Viking Therapeutics Reports Strong Weight-Loss Drug Trial Results
Viking Therapeutics' (NASDAQ: VKTX) weight-loss drug, VK2735, showed promising results in a maintenance study that led to significant investor interest and upgrades from Wall Street analysts. The trial evaluated the effectiveness of injectable doses over time as both an initial treatment and long-term maintenance therapy for obesity. Key findings included 22% adjusted weight loss at week 33 with no plateau observed, along with strong retention rates—97% after switching to biweekly dosing and 90% under monthly dosing. These results highlight the drug's potential as a competitive option in the fast-growing obesity treatment market. The company announced plans for an oral maintenance dose trial later this year following its ongoing Phase 3 subcutaneous study, which could further expand VK2735’s therapeutic applications and commercial appeal.
Tickers: $VKTX
Topics: biotech GLP-1_agonists pharmaceuticals weight-loss_drugs